Replicel

[gmonasco]

it will not be a good business decision to charge 20k or high figures like this.

It might be good business initially, as there are plenty of people who could (and would) pony up that amount. They could always drop the price afterwards to catch the rest of the market.

As a drug the over heads will be low.

Replicel's product is not a "drug"; it's a treatment that requires the replication of hair cells, a process that is neither quick nor inexpensive.